--- title: "WAVE Life Sciences (NASDAQ:WVE) Shares Down 7.6% - Here's What Happened" type: "News" locale: "en" url: "https://longbridge.com/en/news/284618799.md" description: "WAVE Life Sciences (NASDAQ:WVE) shares fell 7.6% to $6.9460, with trading volume down 79% from average levels. Analysts have mixed views, with Mizuho raising its target price to $27 and Weiss Ratings maintaining a 'sell' rating. The company reported a quarterly EPS of ($0.13), beating estimates, and revenue of $38.25 million. Insider selling occurred, with CFO and CEO reducing their stakes. Institutional investors have also adjusted their holdings, with GSK plc acquiring a significant position." datetime: "2026-04-29T17:34:49.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284618799.md) - [en](https://longbridge.com/en/news/284618799.md) - [zh-HK](https://longbridge.com/zh-HK/news/284618799.md) --- # WAVE Life Sciences (NASDAQ:WVE) Shares Down 7.6% - Here's What Happened WAVE Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) shares dropped 7.6% during trading on Wednesday . The company traded as low as $6.94 and last traded at $6.9460. Approximately 883,299 shares traded hands during trading, a decline of 79% from the average daily volume of 4,273,255 shares. The stock had previously closed at $7.52. Get **WAVE Life Sciences** alerts: ## Analyst Ratings Changes - Golden Cross Alert: 3 Stocks With Major Upside Potential WVE has been the topic of a number of research analyst reports. Mizuho lifted their target price on WAVE Life Sciences from $22.00 to $27.00 and gave the stock an "outperform" rating in a research report on Wednesday, March 25th. Weiss Ratings reiterated a "sell (d-)" rating on shares of WAVE Life Sciences in a research report on Monday, April 20th. Wedbush lifted their target price on WAVE Life Sciences from $33.00 to $35.00 and gave the stock an "outperform" rating in a research report on Friday, March 6th. Wall Street Zen cut WAVE Life Sciences from a "sell" rating to a "strong sell" rating in a research report on Sunday, April 12th. Finally, Cantor Fitzgerald lifted their target price on WAVE Life Sciences from $34.00 to $41.00 and gave the stock an "overweight" rating in a research report on Thursday, February 5th. Fourteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, WAVE Life Sciences currently has an average rating of "Moderate Buy" and a consensus target price of $28.44. **Read Our Latest Report on WAVE Life Sciences** ## WAVE Life Sciences Trading Down 6.4% - Wave Life Sciences Rockets 70% on Historic RNA Editing Success The company has a 50 day simple moving average of $10.28 and a 200 day simple moving average of $11.27. The stock has a market capitalization of $1.32 billion, a PE ratio of -5.76 and a beta of -1.32. WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 28th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.21. The firm had revenue of $38.25 million during the quarter, compared to the consensus estimate of $8.45 million. WAVE Life Sciences had a negative return on equity of 85.69% and a negative net margin of 478.35%. On average, equities research analysts predict that WAVE Life Sciences Ltd. will post -1.39 EPS for the current year. ## Insider Buying and Selling - Sarepta Therapeutics Inc.: Why it's a rising gene therapy star In other WAVE Life Sciences news, CFO Kyle Moran sold 3,588 shares of the company's stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $13.45, for a total transaction of $48,258.60. Following the completion of the sale, the chief financial officer directly owned 134,385 shares of the company's stock, valued at $1,807,478.25. This represents a 2.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Paul Bolno sold 10,480 shares of the company's stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $13.45, for a total value of $140,956.00. Following the sale, the chief executive officer directly owned 275,520 shares of the company's stock, valued at approximately $3,705,744. This represents a 3.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 52,373 shares of company stock valued at $757,527 in the last quarter. 23.98% of the stock is currently owned by insiders. ## Hedge Funds Weigh In On WAVE Life Sciences Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. GSK plc acquired a new position in WAVE Life Sciences during the 4th quarter worth approximately $310,177,000. Adage Capital Partners GP L.L.C. increased its position in WAVE Life Sciences by 20.0% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company's stock worth $97,607,000 after purchasing an additional 2,500,000 shares during the period. Price T Rowe Associates Inc. MD increased its position in WAVE Life Sciences by 83.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,407,372 shares of the company's stock worth $125,927,000 after purchasing an additional 3,362,880 shares during the period. Darwin Global Management Ltd. acquired a new position in WAVE Life Sciences during the 4th quarter worth approximately $125,168,000. Finally, Federated Hermes Inc. increased its position in WAVE Life Sciences by 26.5% during the 4th quarter. Federated Hermes Inc. now owns 4,744,520 shares of the company's stock worth $80,657,000 after purchasing an additional 993,827 shares during the period. Institutional investors and hedge funds own 89.73% of the company's stock. ## About WAVE Life Sciences (Get Free Report) WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines. The company's pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington's disease, as well as early-stage cardiovascular and liver indications. ## Recommended Stories - Five stocks we like better than WAVE Life Sciences _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in WAVE Life Sciences Right Now? Before you consider WAVE Life Sciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and WAVE Life Sciences wasn't on the list. While WAVE Life Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [WVE.US](https://longbridge.com/en/quote/WVE.US.md) - [MFG.US](https://longbridge.com/en/quote/MFG.US.md) - [8411.JP](https://longbridge.com/en/quote/8411.JP.md) - [SRPT.US](https://longbridge.com/en/quote/SRPT.US.md) - [GSK.US](https://longbridge.com/en/quote/GSK.US.md) - [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md) - [TROW.US](https://longbridge.com/en/quote/TROW.US.md) - [FHI.US](https://longbridge.com/en/quote/FHI.US.md) - [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md) ## Related News & Research - [Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1 | WVE Stock News](https://longbridge.com/en/news/286925108.md) - [Wave Life Sciences ATS Data Could Support RNA Editing Platform, Wedbush Says](https://longbridge.com/en/news/286602718.md) - [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md) - [Why Location Is the Only Thing That Matters for Nebius Stock](https://longbridge.com/en/news/286822370.md) - [The smartest stock to buy with $1,000 right now](https://longbridge.com/en/news/286600210.md)